Elan Corp.’s impending cash influx will give the drug developer leeway to buy something it lacks: a product.

Elan agreed this month to sell its rights to a multiple sclerosis treatment to Biogen Idec Inc. for $3.25 billion and a share of royalties, leaving it with no medicines and more cash than almost every other specialty pharmaceutical company.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.